{"id":"W4406468796","doi":"10.1080/14796694.2024.2441107","title":"Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Eli Lilly Japan; Chugai Pharmaceutical; EMD Serono; Genentech; Sierra Oncology; Sun Pharma; Rakuten Medical; STCube; FibroGen; Astellas Pharma; Eisai; Regeneron Pharmaceuticals; Natera; Relay Therapeutics; Seagen; Actuate Therapeutics; BeiGene; Taiho Pharmaceutical; Kyowa Kirin Pharmaceutical Development; Pfizer; Incyte; Daiichi Sankyo Europe; Servier; Gilead Sciences; Japan Society for the Promotion of Science; GlaxoSmithKline; Mersana Therapeutics; Japan Agency for Medical Research and Development; Roivant Sciences; Amgen; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Agonist; Sting; Open label; Oncology; Internal medicine; Receptor; Clinical trial","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002476024,0.0002730406,0.000852195,0.0002011748,0.0003436721,0.00002053382,0.0006554472,0.0002742756,0.0001382758],"category_scores_gemma":[0.0001666533,0.000212643,0.0000492819,0.0002345319,0.0002007325,0.0001141627,0.0003463976,0.0003271037,0.00002407662],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001816814,"about_ca_system_score_gemma":0.0005412998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005498669,"about_ca_topic_score_gemma":0.0002007344,"domain_scores_codex":[0.998116,0.0003625875,0.0005735825,0.0004468557,0.00003682562,0.0004641543],"domain_scores_gemma":[0.9985307,0.0003615417,0.0003689309,0.0003978391,0.0003189797,0.00002198864],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.2114149,0.05514358,0.004650345,0.00037871,0.003599133,0.00005499782,0.008016279,0.00002950516,0.3959303,0.004371553,0.03252921,0.2838815],"study_design_scores_gemma":[0.2659111,0.1348951,0.01110419,0.0003844443,0.0006513922,0.00004109901,0.02121307,0.00002486128,0.0662533,0.00009627322,0.4985188,0.0009063044],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912329,0.0008228921,0.0001369871,0.0003022616,0.001998702,0.002287335,0.0001170176,0.00004758084,0.003054265],"genre_scores_gemma":[0.9949525,0.00001617887,0.0005193178,0.0003413303,0.00004076753,0.0002932945,0.0002166958,0.00002653463,0.003593396],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4659896,"threshold_uncertainty_score":0.867133,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01667253931178255,"score_gpt":0.3632815307260697,"score_spread":0.3466089914142871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}